New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2014
10:42 EDTFBHS, THRX, LAMR, PETM, CBSO, TSM, LITB, SONS, WY, WLPHigh option volume stocks
High option volume stocks: FBHS WY SONS LITB TSM CBSO PETM LAMR THRX WLP
News For FBHS;WY;SONS;LITB;TSM;CBSO;PETM;LAMR;THRX;WLP From The Last 14 Days
Check below for free stories on FBHS;WY;SONS;LITB;TSM;CBSO;PETM;LAMR;THRX;WLP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 23, 2014
17:45 EDTCBSOCBS Outdoor COO Kelly departs
CBS Outdoor Americas has announced that Wally Kelly, president and COO since 2013, will be leaving the organization. He will stay at the company for an advisory period until the end of this year.
06:46 EDTPETMPetSmart volatility at low end of historic range
Subscribe for More Information
July 22, 2014
13:46 EDTWLPCourt upholds Obamacare subsidies, NY Times says
Subscribe for More Information
10:43 EDTWLPAppeals court bars subsidies in health care law
A three-judge panel of the D.C. Circuit Court of Appeals struck down part of President Obama's healthcare law by siding today with plaintiffs who argued that the law barred the government from giving subsidies to people in states that chose not to set up their own insurance marketplaces. The appeals court stated, "Because we conclude that the ACA unambiguously restricts the section 36B subsidy to insurance purchased on Exchanges 'established by the State,' we reverse the district court and vacate the IRSís regulation." Twenty-seven states decided against setting up marketplaces, and another nine states partially opted out, according to the Washington Post.
July 21, 2014
12:41 EDTTSMIntel advances after analyst predicts mobile unit rebound coming
Shares of Intel (INTC) are advancing in a down market after Wells Fargo wrote that the company's mobile chip business could rebound significantly in coming quarters. WHAT'S NEW: Intel's mobile chip business could boost the company's growth and even enable it to beat earnings expectations, Wells Fargo wrote in a note to investors today. The chip maker's shipments of 4G modems should start rising significantly in the third quarter or fourth quarter of this year, the firm stated. The company has probably won some deals to provide LTE modems for smartphones and Samsung is likely one of the chip maker's initial customers, the firm wrote. Broadcom's (BRCM) decision to exit the baseband market probably improved Intel's position in the 4G market, Wells Fargo contended. Meanwhile, Intel said that by this year's holiday season, it should be ready to launch chips for mobile devices that are smaller than those of a key competitor, TSMC (TSM), Wells noted. Sales generated by Intel's mobile and communications unit may have bottomed last quarter or could do so during the current quarter, the firm believes. The unit's operating losses are likely to drop throughout this year, before falling sharply in the quarter ended March 2015, Wells estimated. The unit may approach break even by the end of 2015, the firm added. Wells kept an Outperform rating on the stock. WHAT'S NOTABLE: On July 15, Intel reported stronger than expected results for its quarter ended in June. PRICE ACTION: In early afternoon trading, Intel rose 43c, or 1.3%, to $34.13.
07:04 EDTCBSOCBS Outdoor acquires outdoor assets from Van Wagner Communications
Subscribe for More Information
July 20, 2014
12:58 EDTTSMTSMC could drop over 10%, Barron's says
Subscribe for More Information
July 18, 2014
07:20 EDTTSMLG Display added to Asia Focus List, TSMC removed at JPMorgan
Subscribe for More Information
July 17, 2014
14:30 EDTTSMFujitsu to exit chip making, sell plants to ON Semi, United Micro, Nikkei says
Subscribe for More Information
10:00 EDTPETMOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: 21st Century Fox (FOXA) downgraded to Buy from Strong Buy at ISI Group... Charter (CHTR) downgraded to Hold from Buy at Jefferies... Covidien (COV) downgraded to Hold from Buy at Needham... Diageo (DEO) downgraded to Underweight from Neutral at JPMorgan... GNC Holdings (GNC) downgraded to Hold from Buy at Jefferies... International Game (IGT) downgraded to Market Perform from Outperform at BMO Capital... JAVELIN Mortgage (JMI) downgraded to Market Perform from Outperform at JMP Securities... Macquarie Group (MQBKY) downgraded to Underweight from Neutral at JPMorgan... PNC Financial (PNC) downgraded to Neutral from Buy at Compass Point... PetSmart (PETM) downgraded to Sector Perform from Outperform at RBC Capital... Rexam (REXMY) downgraded to Hold from Buy at Deutsche Bank.
06:43 EDTTSMTSMC expects to lose out to competitors in 14/16nm segment, DigiTimes says
Subscribe for More Information
06:19 EDTPETMPetSmart downgraded to Sector Perform from Outperform at RBC Capital
Subscribe for More Information
July 16, 2014
16:34 EDTCBSOCBS Outdoor completes separation from CBS and REIT conversion
Subscribe for More Information
10:48 EDTTSMTSMC falls, levels to watch
Subscribe for More Information
10:35 EDTCBSOOptions with decreasing implied volatility
Subscribe for More Information
10:00 EDTTSMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:08 EDTTSMTSMC downgraded to Negative from Neutral at Susquehanna
06:18 EDTTSMTSMC volatility increases as shares trade near 14-year high
Subscribe for More Information
05:49 EDTTSMStocks with implied volatility movement; SDS TSM
Subscribe for More Information
05:38 EDTTHRXGSK, Theravance initiate Phase III IMPACT study
GlaxoSmithKline (GSK) and Theravance (THRX) announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the 'closed' triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease, or COPD. IMPACT is the first pivotal phase III study in a programme to evaluate a once-daily closed triple combination treatment of an inhaled corticosteroid, or ICS; a long-acting muscarinic antagonist, or LAMA; and a long-acting beta2-adrenergic agonist, or LABA, in patients with COPD. The IMPACT study will enrol approximately 10,000 patients and assess whether the combination of FF, or fluticasone furoate, an ICS, UMEC, or umeclidinium, a LAMA, and VI, or vilanterol, a LABA, all delivered in GSK's Ellipta inhaler, can reduce the annual rate of moderate and severe exacerbations compared with two approved once daily COPD treatments, Relvar/Breo Ellipta, FF/VI, which is an ICS/LABA combination, and Anoro Ellipta, UMEC/VI, which is a LAMA/LABA combination.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use